Breakthrough Science for Better Health

Passionately committed to bettering the lives of patients with cardiorenal diseases.
Learn About Us

Patients

We are committed to scientific and clinical integrity with a passionate pursuit of medical innovation to deliver the highest-quality therapeutics to better the lives of underserved patients.

LEARN MORE

Programs

Our pipeline of gut-restricted therapies is concentrated on providing better medicines to patients in need.

LEARN MORE

Investors

We are executing a strategic plan focused on bringing important medicines to patients in need, while generating value for our shareholders.

LEARN MORE

THE FACTS

740,000 ESRD patients with hyperphosphatemia in major developed countries
~2 Million people in U.S. with CKD and/or heart failure have hyperkalemia
~90,000 people with ESRD die in the U.S. each year – a number higher than those with breast cancer, hepatitis C and HIV combined
~95% of CKD patients on dialysis need phosphate control
Impact

Making Better Medicine For Patients In Need

We are advancing our lead product, tenapanor, for the treatment of hyperphosphatemia in patients with CKD who are on dialysis.

Learn More About Our Tenapanor Programs
Sep
03
2019
09.03.2019
Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment

Ardelyx, Inc. (Nasdaq: ARDX), today reported positive results from AMPLIFY, a pivotal Phase 3 study of tenapanor in combination with phosphate binders in patients with chronic kidney disease (CKD) on…
Mar
07
2019
03.07.2019
Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology

Ardelyx, Inc. (Nasdaq: ARDX) today announced the publication in the Journal of the American Society of Nephrology (JASN) of results from the first of two Phase 3 pivotal trials for…
Mar
06
2019
03.06.2019
Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results for the…
Feb
21
2019
02.21.2019
Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at…
Feb
07
2019
02.07.2019
Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan

Ardelyx, Inc. (NASDAQ: ARDX, Ardelyx) today announced that its collaboration partner in Japan, Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, Kyowa Hakko Kirin), has initiated a Phase 2 clinical study…
Nov
13
2018
11.13.2018
Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C

Ardelyx, Inc. (Nasdaq: ARDX), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tenapanor for the treatment of patients…
Nov
07
2018
11.07.2018
Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights

Ardelyx, Inc. (Nasdaq: ARDX), today reported business highlights and financial results for the third quarter ended September 30, 2018.
Oct
26
2018
10.26.2018
Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus

Ardelyx, Inc. (Nasdaq: ARDX), today announced the presentation of preclinical data suggesting therapeutic synergy of tenapanor in combination with sevelamer, the current standard-of-care phosphate binder treatment for hyperphosphatemia, or elevated…
Oct
08
2018
10.08.2018
Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting

Ardelyx, Inc. (Nasdaq: ARDX), today announced that new data from its long-term safety trial of tenapanor for irritable bowel syndrome with constipation (IBS-C), the T3MPO-3 trial, were presented this weekend…
Oct
04
2018
10.04.2018
Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders

Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an investor event called “Renal Day” on Thursday, Oct. 11, 2018, from 8 to 10 a.m. ET in New York…
Sep
13
2018
09.13.2018
Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration

Ardelyx, Inc. (Nasdaq: ARDX), today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting U.S. marketing authorization of tenapanor for the…
Aug
29
2018
08.29.2018
Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor’s Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption

Ardelyx, Inc. (Nasdaq: ARDX), today announced that the novel mechanism of action for tenapanor for the treatment of hyperphosphatemia, or elevated serum phosphorus, has been published in the peer-reviewed journal…

Everyone here is excited about what we’re creating and what it could mean for patients.

- Kelli, HR

Make An Impact With Us

PIPELINE

PROGRAM
INDICATION
RESEARCH
PHASE 1
PHASE 2
PHASE 3
APPROVED
Cardiorenal Programs
Tenapanor
ESRD Hyperphosphatemia
(NHE3 Inhibitor)
RDX011
Cardiorenal Indications
(NHE3 Inhibitor)
RDX013
Hyperkalemia
(Potassium Secretagogue)
Gastrointestinal Programs
Tenapanor
IBS-C
(NHE3 Inhibitor)
RDX011
GI Indications
(NHE3 Inhibitor)
Learn More About Our Programs